These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

657 related items for PubMed ID: 22632106

  • 1. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability.
    Miller JM, Beig A, Carr RA, Spence JK, Dahan A.
    Mol Pharm; 2012 Jul 02; 9(7):2009-16. PubMed ID: 22632106
    [Abstract] [Full Text] [Related]

  • 2. The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: increased apparent solubility and drug flux through the intestinal membrane.
    Dahan A, Beig A, Ioffe-Dahan V, Agbaria R, Miller JM.
    AAPS J; 2013 Apr 02; 15(2):347-53. PubMed ID: 23242514
    [Abstract] [Full Text] [Related]

  • 3. The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations.
    Miller JM, Beig A, Carr RA, Webster GK, Dahan A.
    Mol Pharm; 2012 Mar 05; 9(3):581-90. PubMed ID: 22280478
    [Abstract] [Full Text] [Related]

  • 4. Head-To-Head Comparison of Different Solubility-Enabling Formulations of Etoposide and Their Consequent Solubility-Permeability Interplay.
    Beig A, Miller JM, Lindley D, Carr RA, Zocharski P, Agbaria R, Dahan A.
    J Pharm Sci; 2015 Sep 05; 104(9):2941-7. PubMed ID: 25989509
    [Abstract] [Full Text] [Related]

  • 5. Advantageous Solubility-Permeability Interplay When Using Amorphous Solid Dispersion (ASD) Formulation for the BCS Class IV P-gp Substrate Rifaximin: Simultaneous Increase of Both the Solubility and the Permeability.
    Beig A, Fine-Shamir N, Lindley D, Miller JM, Dahan A.
    AAPS J; 2017 May 05; 19(3):806-813. PubMed ID: 28204967
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The Solubility-Permeability Trade-Off of Progesterone With Cyclodextrins Under Physiological Conditions: Experimental Observations and Computer Simulations.
    Sun L, Zhang B, Sun J.
    J Pharm Sci; 2018 Jan 05; 107(1):488-494. PubMed ID: 29031956
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Striking the Optimal Solubility-Permeability Balance in Oral Formulation Development for Lipophilic Drugs: Maximizing Carbamazepine Blood Levels.
    Beig A, Miller JM, Lindley D, Dahan A.
    Mol Pharm; 2017 Jan 03; 14(1):319-327. PubMed ID: 27981848
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Oral delivery of lipophilic drugs: the tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations.
    Beig A, Agbaria R, Dahan A.
    PLoS One; 2013 Jan 03; 8(7):e68237. PubMed ID: 23874557
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.